Business
Gemini Therapeutics Announces Poster Presentation at AAO 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments
About this update from Disc Medicine, Inc.
[{"type":"text","content":" CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nGemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today announced that Raj Maturi, M.D., Adjunct Clinical Assistant Professor of Ophthalmology at Indiana University School of Medicine and an investigator in the ReGAtta study, will present a poster at the 2021 Annual Meeting of the American Academy of Ophthalmology (AAO), which is being held virtually and in-person at the Ernest N. Morial Convention Center, New Orleans, LA on November 12 – 15, 2021.\n\nDetails of the virtual poster at the AAO meeting include:\n\nTitle: Phase 2a Open Label Study of GEM103 in Genetically Selected Geographic Atrophy (GA) Subjects\n\nThis poster (PO329) features newly available data that updates the May 2021 initial data from the Company’s ongoing ReGAtta Phase 2a study of GEM103. In summary, GEM103 continues to be generally well-tolerated:\n\n\nThrough 510 intravitreal administrations of GEM 103, no ocular serious adverse events related to study drug reported, no ocular adverse events leading to study discontinuation, and no anti-GEM103 antibodies detected in plasma.\n\n\n\n17 patients (27.4%) experienced mild to moderate ocular adverse events in the study eye including two intraocular inflammation adverse events. Inflammation was mild or moderate and the patients recovered without recurrence and no study drug interruption. The moderate case was unrelated to GEM103 and the patient had a history of autoimmune disease.\n\n\n\nNo increased risk observed for Choroidal Neovascularization (CNV). Two adverse events of neovascular AMD in the study eye occurred; in both cases, there were no definitive evidence of CNV by independent reading center’s analysis of the retinal imaging. These events were determined to be unrelated to GEM103 and there was no impact on vision.\n\n\nInformation on Gemini Therapeutics, including GEM103 and initial ReGAtta data, and the e-poster presented at AAO 2021, can be found on Gemini Therapeutics’ website under the Investors & Media section: Events and Presentations.\n\nAbout Gemini Therapeutics\n\nGemini Therapeutics is a clinical stage precision medicine company developing novel therapeutic compounds to treat genetically defined age-related macular degenerati...